Events 2012 - 2011 - 2010 - 2009 - 2008
2012
February 13th, 2012, InnaVirVax lands $ 4.9 million in series B funding round (see press release in English ).
2011
December 1rst, 2011, World AIDS Day, Joël Crouzet is interviewed by David Dauba on BFM Business TV, in the New-York Paris program (listen to the interview at around minute 11'30).
October 2011, France 3 , the French TV channel (see video) and les Echos, the renowned French business newspaper (read article) acknowledge the main step that InnaVirVax just made in the development of VAC-3S.
October 2011, InnaVirVax recieved a clinical trial authorization from the French drug agency (AFSSAPS) to run a Phase I/IIa clinical trial of its VAC-3S vaccine candidate .
July 2011, InnaVirVax is an awardee of the 2011 edition of the "Tremplin Entreprises" from the French Senate .
June 2011, InnaVirVax annonces the completion of the non clinical GLP toxicity studies of its vaccine candidate VAC-3S. The results show the lack of toxicity of VAC-3S at the tested doses.
May 2011, InnaVirVax had been selected by Challenges, the French weekly magazine of economic affairs, as one of the 100 most promising start-up for an investment, (Challenge, May 2011, 256, pg 60-80).
March 2011, InnaVirVax and scientists from Inserm, University Pierre & Marie Curie (Paris) and University Paris-Sud (Paris), presented results showing the prognosis value of anti-3S antibodies at the International Workshop on HIV Observational Databases in Prague .
January 2011, InnaVirVax initiates the regulatory non clinical toxicology studies of its vaccine candidate VAC3S.
2010
October 2010, the process development of InnaVirVax VAC3S vaccine candidated is completed.
July 2010, Fausther-Bovendo et al. (Fausther-Bovendo et al, HIV gp41 Engages gC1qR on CD4+ T Cells to Induce the Expression of an NK Ligand through the PIP3/H2O2 Pathway. 2010.
PLoS Pathogens, 6:1000975)
published the identification of the
receptor the HIV-1 3S peptide on CD4 T cells.
April 2010, V. Vieillard et al. published an article entitled " Specific Phenotypic and Functional Features of Natural Killer Cells from HIV-Infected Long-Term Nonprogressors and HIV Controllers " in
J. Acquir. Immune Defic. Syndr. 53:564-573 . This artile shows that NK cells from long-term non progressor and HIV controller patients exhibit particular phenotypic and functional features and suggest a consistent continuous involvement of the innate immune system to control viral replication.
February 2010, InnaVirVax became a member of
France Biotech, the French Biotechnology company organization.
January 2010, InnaVirVax has agreed to work with
piCHEM for the process development and the manufacturing of its vaccine candidate.
January 2010, InnaVirVax has selected a VAC3S vaccine candidate for development and has initiated the non clinical development of its vaccine candidate.
2009
December 2009, InnaVirVax presented to the
AFSSAPS (the French Drug Agency) its VAC3S project during an "innovative meeting".
December 2009, InnaVirVax became a member of
Medicen, the Paris Region Biotechnology cluster dedicated to innovative therapies and advanced technologies in healthcare.
October 2009, Inserm and Assistance Publique - Hôpitaux de Paris granted a
worldwide exclusive licence to InnaVirVax on the patents and know-how related to the projects developped by InnaVirVax.
August 2009, InnaVirVax was granted the status of
"Jeune Entreprise Innovante" (Young Innovative Company status) by the French Autorities which gives a 7 year tax saving benefit up to the end of year 2015.
July 2009, V. Vieillard et al.published in
AIDS 2009, 23:1077-1087 , a paper entitled "HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells". This publication deciphers the mecanism by which HIV-infected cells are resistant to NK cells-mediated lysis, contrary to CD4+ T cells put into contact to the 3S peptide from gp41 of HIV-1.
June 2009, successful closing of InnaVirVax series A equity investment round with CapDecisif Management and G1J-Ile de France for a € 1,1 million.
2008
October 2008, Biotech et Finance published an article entitled « government grant plebiscite for InnaVirVax ».
InnaVirVax has obtained a € 1,15 million grant from the
ANR (the French National Research Agency) within the
BiotecS call for proposal for its HIV therapeutic vaccine project (VAC3S) (
July 2008).
InnaVirVax is incubated at the
Genopole of Evry, the Paris Region BioPark (
July 2008).
InnaVirVax incorporation (March 2008).
A paper entitled “A vaccine strategy against AIDS: An HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques” with Patrice Debré and Vincent Vieillard as co-authors is published in Proc. Natl. Acad. Sci., 2008, 105(6): 2100–2104. This publication establishes in cynomolgus the proof of concept of the vaccine approach developed by InnaVirVax (January 2008).
